15.11
Modelli farmacodinamici: modello lineare concentrazione–effetto
Il modello lineare concentrazione–effetto, fondato sul principio secondo cui l'effetto farmacologico (E) è direttamente proporzionale alla concentrazi…
Il modello lineare concentrazione-effetto assume che l'effetto farmacologico, E, sia direttamente proporzionale alla concentrazione plasmatica del farmaco, Cp.
Quando si traccia la concentrazione plasmatica del farmaco rispetto a un effetto, la curva concentrazione-effetto è approssimativamente lineare al di sotto di EC50.
Il modello sostiene che l'effetto del farmaco aumenti continuamente con l'aumento delle concentrazioni fino a raggiungere il massimo effetto farmacologico, Emax.
Tuttavia, questa relazione lineare non si applica a un'ampia gamma di concentrazioni.
Nonostante queste limitazioni, il modello è ampiamente utilizzato per valutare gli effetti dei farmaci sulla ripolarizzazione cardiaca, misurati dall'intervallo QT su un elettrocardiogramma o un ECG.
Ad esempio, secondo questo modello, il grafico tra la concentrazione di moxifloxacina e il prolungamento dell'intervallo QTc produce una curva lineare.
Inoltre, la relazione concentrazione-QTc svolge un ruolo chiave nella valutazione regolatoria della FDA dei nuovi farmaci per valutare il rischio proaritmico.
View the full transcript and gain access to JoVE Core videos
Q1: What is the linear concentration-effect model in pharmacodynamics?
The linear concentration-effect model assumes that pharmacological effect (E) is directly proportional to plasma drug concentration (Cp). This model simplifies the Emax model when drug concentrations are significantly below the EC50 threshold. The concentration-effect curve appears approximately linear in this range, with drug effect increasing continuously until reaching maximum pharmacological effect (Emax).
Q2: When is the linear concentration-effect model applicable?
The linear concentration-effect model applies when plasma drug concentrations are markedly below the EC50 threshold, where the relationship between concentration and effect remains approximately linear. However, this linearity does not hold across wide concentration ranges, limiting the model's applicability to comprehensive pharmacodynamic modeling. It is most useful for evaluating specific drug effects within restricted concentration windows.
Q3: How is the linear concentration-effect model used in cardiac safety assessment?
The linear concentration-effect model is widely used to evaluate drug effects on cardiac repolarization, measured by the QT interval on an electrocardiogram (ECG). For example, the plot between moxifloxacin concentration and QTc interval prolongation yields a linear curve. This concentration-QTc relationship plays a key role in the FDA's regulatory evaluation of new drugs for assessing proarrhythmic risk.
Q4: What are the limitations of the linear concentration-effect model?
The linear concentration-effect model assumes continuous effect augmentation with increasing drug concentrations, but this assumption does not hold across extensive concentration ranges. The model's linearity is restricted to conditions where concentrations remain significantly below EC50. These inherent limitations confine its applicability to specific pharmacodynamic scenarios rather than comprehensive drug effect modeling.
Q5: How does the linear model relate to the Emax model?
The linear concentration-effect model emerges as a pivotal simplification of the Emax model for conditions where plasma drug concentration is significantly less than EC50. Under these restricted conditions, the nonlinear Emax relationship approximates a linear trajectory. This simplification allows for straightforward analysis while maintaining accuracy within the applicable concentration range.
Q6: Why is the concentration-QTc relationship important for drug development?
The concentration-QTc relationship facilitates the US FDA's regulatory review processes, particularly in assessing proarrhythmic risks associated with novel therapeutic agents. This analysis has been extensively applied in characterizing moxifloxacin and developing new pharmacological entities. The linear model's utility in this context underscores its significance in advancing drug safety evaluations during regulatory approval.
Q7: What does EC50 represent in the linear concentration-effect model?
EC50 represents the plasma drug concentration at which 50% of the maximum pharmacological effect is achieved. The linear concentration-effect model applies when actual drug concentrations remain significantly below this EC50 threshold. Above EC50, the linear relationship breaks down and the model's assumptions no longer hold, requiring alternative pharmacodynamic models for accurate predictions.